CDC&P - MMWR Vol. 65 / No. RR-3

MMWR Recommendations and Reports Vol. 65, No. RR-3 July 29, 2016   PDF   In this report U.S. Medical Eligibility Criteria for Contraceptive Use, 2016 Kathryn M. Curtis, PhD; Naomi K. Tepper, MD; Tara C. Jatlaoui, MD, et al. MMWR Recomm Rep 2016;65:1–104 The 2016 U.S. Medical Eligibility Criteria for Contraceptive Use (U.S. MEC) comprises recommendations for the use of specific contraceptive methods by women and men who have certain characteristics or medical conditions. Notable updates since the 2010 U.S. MEC include the addition of recommendations for women with cystic fibrosis, women with multiple sclerosis, and women receiving certain psychotropic drugs or St. John's wort; revisions to the recommendations for emergency contraception, including the addition of ulipristal acetate; and revisions to the recommendations for postpartum women; women who are breastfeeding; women with known dyslipidemias, migraine headaches, superficial venous disease, gestational trophoblastic disease, sexually transmitted diseases, and human immunodeficiency virus; and women who are receiving antiretroviral therapy. These recommendations are a companion document to the CDC U.S. Selected Practice Recommendations for Contraceptive Use, 2016. MMWR Masthead Department of Health and Human Services Centers for Disease Control and Prevention   The CDC has reached over 1 million email subscribers. Thank you for your support. Modify/Update Subscriber Preferences or Unsubscribe | Learn about CDC Updates Questions or problems? Please contact support@govdelivery.com.             This email was sent to mantiskhiralla@gmail.com using GovDelivery,on behalf of: Centers for Disease Control and Prevention • 1600 Clifton Rd • Atlanta, GA 30333 • 1-800-CDC-INFO (800-232-4636)